NICE(UK): Donidalorsen can be used as an option to prevent recurrent attacks of hereditary angioedema (HAE) in people 12 years and over, only if: i) they have 2 or more… read more.
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or… read more.
Ultragenyx Pharmaceutical announced that the FDA granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX 401, in adult and pediatric patients eight years and older with… read more.
Lantheus Holdings, Inc. announced FDA approval of TAUKLARIFY (florquinitau F 18 injection), also referred to as MK 6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of… read more.
The MHRA has approved Romvimza (vimseltinib ) to treat adult patients with tenosynovial giant cell tumour (TGCT) when it impacts movement or where surgery is not an option. TGCT (Giant cell… read more.
Bristol Myers Squibb announced that the FDA has approved ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple… read more.
Daiichi Sankyo and AstraZeneca announced that Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in China for the first-line treatment of adult patients with unresectable or… read more.
NICE: Finerenone can be used, within its marketing authorisation, as an option to treat symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults. Why… read more.
Bavarian Nordic A/S announced that the European Commission has adopted the recent Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the approval of a type… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorised orforglipron (Foundayo), making the UK the first country in Europe to approve this GLP-1 tablet for weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased… read more.
Outlook Therapeutics, Inc. announced that the FDA has approved Lytenava (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The approval establishes… read more.
According to the Medicines and Healthcare products Regulatory Agency (MHRA) website, an intravesical delivery system containing gemcitabine (Inqlexzo) has been authorised for the treatment of adults for certain… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
